LS&A Is Handling Zofran Birth Defect Cases

Lewis Saul & Associates, P.C. is actively representing families from throughout Maine and the rest of the United States with children who were born with birth defects after their mothers used Zofran (ondansetron) during pregnancy. For over a decade, GlaxoSmithKline (GSK) promoted Zofran “off-label” for the treatment of nausea and vomiting during pregnancy when the […]

By |May 21st, 2015|Breaking News|Comments Off on LS&A Is Handling Zofran Birth Defect Cases

LS&A Investigating Xarelto-Induced Bleeding Cases

Xarelto is a blood thinner used to prevent blood clots in persons with atrial fibrillation. Xarelto has been aggressively marketed by Bayer Healthcare Pharmaceuticals (Bayer) and Johnson & Johnson as the next generation of blood thinners intended to replace Coumadin (warfarin). Although not without some minor inconveniences, Coumadin is a tried and true blood thinning […]

By |May 21st, 2015|Breaking News|Comments Off on LS&A Investigating Xarelto-Induced Bleeding Cases

LS&A Files Depuy Pinnacle Hip Implant Case in Maine

On February 23, 2015, Lewis Saul & Associates, P.C. filed a product liability lawsuit on behalf of its client, James Vadas, against Johnson & Johnson, Depuy Orthopaedics and related entities. The case was filed in the United States District Court for the District of Maine. In March 2009. Mr. Vadas underwent a total hip arthroplasty […]

By |May 21st, 2015|Breaking News|Comments Off on LS&A Files Depuy Pinnacle Hip Implant Case in Maine

Low-T Drugs Causing Heart Attacks and Strokes

Two recent epidemiology studies demonstrate that testosterone replacement therapy drugs (“Low-T drugs”) are causing heart attacks, strokes and blood clot injuries in some male users. Low-T drugs include Androgel, Androderm, Axirom, Bio-T-Gel, Delatestryl, Depo-Testosterone, Fortesta, Striant, Testim, and Testopel. Since the beginning of 2014, the United States Food and Drug Administration has warned on two […]

By |May 21st, 2015|Breaking News|Comments Off on Low-T Drugs Causing Heart Attacks and Strokes

Actos Bladder Cancer Settlement on the Horizon

According to sources close to the negotiations and recent press reports, Takeda Pharmaceuticals has offered $2.2 billion to resolve approximately 8,000 bladder cancer cases filed against the company in federal and state courts around the United States. The settlement would end years of litigation surrounding claims that Takeda ignored and downplayed concerns that Actos can […]

By |May 21st, 2015|Breaking News|Comments Off on Actos Bladder Cancer Settlement on the Horizon